Marion Mccourt Sells 1,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Marion Mccourt sold 1,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $783.91, for a total value of $783,910.00. Following the transaction, the executive vice president now directly owns 19,803 shares in the company, valued at approximately $15,523,769.73. The transaction was disclosed in a filing with the SEC, which is available at this link.

Marion Mccourt also recently made the following trade(s):

• On Monday, October 2nd, Marion Mccourt sold 1,038 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $827.00, for a total value of $858,426.00.

Regeneron Pharmaceuticals Stock Down 0.2 %

Regeneron Pharmaceuticals stock opened at $816.90 on Friday. The firm has a market cap of $88.68 billion, a price-to-earnings ratio of 21.59, a price-to-earnings-growth ratio of 2.37 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 52 week low of $668.00 and a 52 week high of $853.97. The business’s 50-day moving average price is $822.11 and its 200 day moving average price is $781.20. The company has a quick ratio of 4.64, a current ratio of 5.45 and a debt-to-equity ratio of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $11.59 EPS for the quarter, topping the consensus estimate of $9.58 by $2.01. The firm had revenue of $3.36 billion for the quarter, compared to analyst estimates of $3.23 billion. Regeneron Pharmaceuticals had a return on equity of 19.19% and a net margin of 33.93%. Regeneron Pharmaceuticals’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period last year, the company earned $9.98 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.11 earnings per share for the current year.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently bought and sold shares of REGN. NewSquare Capital LLC grew its holdings in Regeneron Pharmaceuticals by 1,450.0% in the first quarter. NewSquare Capital LLC now owns 31 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 29 shares during the period. Sunbelt Securities Inc. acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $25,000. Manchester Capital Management LLC grew its holdings in Regeneron Pharmaceuticals by 740.0% in the first quarter. Manchester Capital Management LLC now owns 42 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 37 shares during the period. BerganKDV Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals by 444.4% in the second quarter. BerganKDV Wealth Management LLC now owns 49 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 40 shares during the period. Finally, Activest Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $40,000. 84.15% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

REGN has been the subject of a number of analyst reports. Piper Sandler upped their price objective on Regeneron Pharmaceuticals from $885.00 to $895.00 and gave the stock an “overweight” rating in a research note on Friday. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $720.00 to $992.00 in a research note on Monday, August 21st. Barclays upped their price objective on Regeneron Pharmaceuticals from $900.00 to $925.00 and gave the stock an “overweight” rating in a research note on Monday, August 21st. Bank of America upped their price objective on Regeneron Pharmaceuticals from $665.00 to $680.00 in a research note on Friday, September 29th. Finally, Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $720.00 to $992.00 in a research note on Monday, August 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $907.96.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.